Clinicopathologic features and results of transcatheter arterial chemoembolization for osteosarcoma

Cardiovasc Intervent Radiol. 2007 Mar-Apr;30(2):201-6. doi: 10.1007/s00270-005-0302-y.

Abstract

Purpose: To evaluate the effect of transcatheter arterial chemoembolization (TACE) for osteosarcoma and to describe the clinicopathologic features produced by TACE as well as the effect of different embolic materials.

Methods: From January 1998 to December 2003, preoperative TACE was carried out in 32 patients. The preoperative and postoperative clinical response, levels of alkaline phosphatase (AKP), leukocyte count, and clinicopathologic features were recorded. We also compared the effect of different embolic materials: adriblastine gelatin microspheres, anhydrous alcohol, common bletilla tuber, and gelatin sponge particles.

Results: The levels of AKP were significantly decreased after treatment (p < 0.05), but there was no significant difference in the leukocyte count. Large areas of necrosis were found histologically within 85.5% tumors after TACE. Embolic agents such as adriblastine microspheres, anhydrous alcohol, and common bletilla tuber have better clinical effects than gelatin sponge particles, but there was no significant difference among the first three embolic materials. After treatment, no serious complications were noted. During successful follow-up for 86 months, the survival rate after TACE at 1, 2, and 5 years was 95.5%, 72%, and 42% respectively.

Conclusion: TACE accelerated tumor necrosis and shrank the tumor volume, thus making adequate tumor resection possible. The optimal time to operate is 10-14 days after TACE. TACE in combination with limb salvage surgery and postoperative periodical chemotherapy may be beneficial for increasing local control rates.

MeSH terms

  • Adolescent
  • Adult
  • Alkaline Phosphatase / blood
  • Alkaline Phosphatase / drug effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood
  • Bone Neoplasms / blood
  • Bone Neoplasms / mortality
  • Bone Neoplasms / pathology*
  • Bone Neoplasms / therapy*
  • Catheterization, Peripheral*
  • Chemoembolization, Therapeutic* / adverse effects
  • Child
  • Cisplatin / administration & dosage
  • Epirubicin / administration & dosage
  • Female
  • Femoral Artery
  • Femur / pathology
  • Follow-Up Studies
  • Humans
  • Humerus / pathology
  • Leukocyte Count
  • Limb Salvage
  • Male
  • Methotrexate / administration & dosage
  • Osteosarcoma / blood
  • Osteosarcoma / mortality
  • Osteosarcoma / pathology*
  • Osteosarcoma / therapy*
  • Severity of Illness Index
  • Tibia / pathology
  • Treatment Outcome
  • Tumor Burden / drug effects

Substances

  • Biomarkers, Tumor
  • Epirubicin
  • Alkaline Phosphatase
  • Cisplatin
  • Methotrexate